Storys zum Thema Health

11.10.2006 – 08:33
Bristol-Myers Squibb Medical Imaging
Bristol-Myers Squibb Medical Imaging Receives European Commission Marketing Authorisation for Its Ultrasound Contrast Agent LUMINITY(TM) (perflutren lipid microsphere)
N. Billerica, Massachusetts (ots/PRNewswire) - Bristol-Myers Squibb Medical Imaging announced today that the European Commission has granted marketing authorisation for LUMINITY(TM), an ultrasound contrast agent, for use in patients with suboptimal echocardiograms who have suspected or established ...
mehr
05.10.2006 – 15:10
Isotechnika Inc.
Isotechnika Reports Final Safety and Efficacy Data From Phase III Psoriasis Extension Trial
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA) reports final safety and efficacy data subsequent to 60 weeks of continuous treatment with ISA247. All safety and efficacy endpoints were met. Patients completing the 24 week Canadian Phase III SPIRIT trial were given the opportunity to continue ISA247 therapy at a 0.3 mg/kg twice daily oral dose ...
mehr
05.10.2006 – 14:06
Xenomics, Inc.
Xenomics Announces Development of a New Method for Isolation of Cell-Free Nucleic Acids From Urine
New York (ots/PRNewswire) - - Prototype Research Kits Approach Commercialization Phase and Target the Growing Field of Genomic-Based Molecular Diagnostics Xenomics, Inc. (OTC Bulletin Board: XNOM; FWB:XE7), the source of next-generation medical DNA diagnostic tests, today announced that it has developed a new method for the isolation of low molecular ...
mehr
05.10.2006 – 12:05
Roche Pharmaceuticals
FUZEON Combined With New Investigational HIV Drug Results in Remarkably High Number of HIV Patients Achieving Undetectable Viral Load
Basel (ots/PRNewswire) - - Results Unveiled at ICAAC Show That Over 90% of Treatment-Experienced Patients Achieve Treatment Goal of Undetectable Viral Load Exciting new clinical data demonstrate that 90 to 95 percent of treatment-experienced HIV patients who initiate therapy with FUZEON(R) (enfuvirtide) ...
mehr
05.10.2006 – 09:39
PharmaMar
Successful Planned Independent Analysis of Pivotal Phase III Trial of YONDELIS(R) in Ovarian Cancer
Madrid (ots/PRNewswire) - PharmaMar today announced the successful planned review by the Independent Data Monitoring Committee (IDMC) of the YONDELIS(R) (trabectedin) Phase III pivotal clinical trial in ovarian cancer, known as OVA-301. The IDMC recommended that the present study should continue without ...
mehr
04.10.2006 – 15:08
Isotechnika Inc.
Isotechnika Receives No Objection Letter From Health Canada for Second Phase III Psoriasis Clinical Trial
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company received a No Objection Letter from Health Canada to conduct a pivotal Phase III European /Canadian clinical trial for the treatment of moderate to severe psoriasis with its lead immunosuppressive drug, ISA247. The Company ...
mehr

03.10.2006 – 15:11
Isotechnika Inc.
Isotechnika Receives European Patent for Lead Immunosuppressive Drug, ISA247
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has been issued European Patent No. EP0991660 for its lead immunosuppressive drug, ISA247. The patent entitled "DEUTERATED AND UNDEUTERATED CYCLOSPORINE ANALOGS AND THEIR USE AS IMMUNOMODULATING AGENTS" is the ninth patent to be issued internationally in this patent family. ...
mehr
02.10.2006 – 15:47
AstraZeneca GmbH
Herceptin and ARIMIDEX(TM) Combination Improves Patient Outcomes in Advanced HER2-Positive Breast Cancer
Macclesfield, England (ots/PRNewswire) - - For International Journalists - Not for US Media New data, presented for the first time today, show that a combination of ARIMIDEX(TM)(anastrozole) plus Herceptin (trastuzumab) is a better treatment option than hormonal therapy alone, for women with a certain ...
mehr
02.10.2006 – 15:14
Isotechnika Inc.
Isotechnika Receives Approval From the German Competent Authority for a Pivotal Phase III Psoriasis Clinical Trial
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company received approval from the German Competent Authority to conduct a pivotal Phase III clinical trial for the treatment of moderate to severe psoriasis with its lead immunosuppressive drug, ISA247. The Phase III ...
mehr
29.09.2006 – 17:40
sanofi-aventis Group
Sanofi Pasteur and the Pediatric Dengue Vaccine Initiative Partner Against Dengue Fever
NEW- YORK, September 29 (ots/PRNewswire) - Sanofi Pasteur, the vaccines business of sanofi-aventis, and the Pediatric Dengue Vaccine Initiative (PDVI) announced today their partnership to help develop and make a Dengue vaccine widely available for the global prevention of Dengue fever, the second most widespread tropical disease after malaria. Dengue fever ...
mehr
29.09.2006 – 10:12
PharmaMar
PharmaMar Reports New Data on Kahalalide-F and Aplidin(R) at ESMO Congress
Istanbul, Turkey (ots/PRNewswire) - PharmaMar, the biopharmaceutical company specialising in cancer therapy, announces today that it is to present new data from two of its clinical compounds, Kahalalide F and Aplidin(R), at the 31st European Society for Medical Oncology Congress (ESMO) being held in Istanbul, Turkey from 29 September to 3 October 2006. Data will ...
mehr
28.09.2006 – 10:03
AstraZeneca GmbH
PHASE III Study Compares Vandetanib (Zactima(TM), ZD6474) to Erlotinib in Advanced Lung Cancer
Alderley Park, England (ots/PRNewswire) - - First Patient Enrolled in Pivotal International Randomised, Double-Blind Study of Vandetanib Versus Erlotinib FOR NON-US HEALTHCARE PROFESSIONAL PRESS ONLY AstraZeneca (NYSE:AZN) today announced the start of enrolment into a new Phase III study of the novel ...
mehr

26.09.2006 – 09:05
Cordis Medizinische Apparate GmbH
Cordis Corporation Launches CYPHER SELECT(TM) Plus Stent
Paris (ots/PRNewswire) - - Shipment of First Third-Generation Drug-eluting Stent Starts Cordis Corporation, the world leader in the drug-eluting stent market, announced today the launch of the CYPHER SELECT(TM) Plus Stent. The first third-generation drug-eluting stent is now available to physicians and patients in many markets around the world, including countries in Western and Eastern Europe, Asia Pacific ...
mehr
26.09.2006 – 08:03
sanofi-aventis Group
Sanofi pasteur Cell Culture-Based Seasonal Influenza Vaccine Enters First Clinical Trial
SWIFTWATER, Pennsylvania & LYON, France, September 26 (ots/PRNewswire) - - Flu Vaccine Based on New Technology Within U.S. Government Preparedness Program Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), initiated its first clinical study today with a new generation of seasonal influenza vaccine produced using cell ...
mehr
21.09.2006 – 15:58
Medify Solutions Ltd.
Medify Solutions Limited (Pink Sheets - MDFY) - Announces Billing Solution
Toronto, Canada (ots/PRNewswire) - Medify Solutions Limited (Pink Sheets - MDFY), today announced that it has signed an agreement with AlwaysON, a leading provider of managed IP communications services. This contract will provide the underpinning network infrastructure and telecommunication services for the rollout and delivery of the MedifyRemote application to ...
mehr
19.09.2006 – 14:45
sanofi-aventis Group
Sanofi pasteur Broadens Pandemic Preparedness With First Clinical Trial of Novel Cell Based H7N1 Vaccine
Lyon, France (ots/PRNewswire) - Sanofi pasteur, the vaccines business of the sanofi-aventis Group, has within the framework of FLUPAN, a collaborative research project funded by the European Commission, generated the first clinical trial lot of a new generation of H7N1 pandemic vaccine. This trial will broaden ...
mehr
19.09.2006 – 09:05
World Federation for Mental Health
Young Physicians Call for Better Medical School Training in Depression
Paris (ots/PRNewswire) - - Multi-National Survey Highlights Gaps in PCPs Knowledge About Depression and Painful Physical Symptoms Nine of 10 young primary care physicians (PCPs) believe medical school training about depression -- specifically regarding its painful physical symptoms -- needs to be improved, according to findings from a multi-national survey ...
mehr
18.09.2006 – 21:04
Pfizer AG
Pfizer's Lyrica(R) Approved in Europe for Difficult-to-Treat Nerve Pain
New York (ots/PRNewswire) - - Lyrica's neuropathic pain indication broadened to include central nerve pain; Central nerve pain is associated with conditions such as spinal cord injury, stroke, and multiple sclerosis - A robust and unprecedented clinical program involving more than 10,000 patients supports Lyrica's efficacy and safety in ...
mehr

18.09.2006 – 14:19
AstraZeneca GmbH
New Data Offers Hope to Patients With Bipolar Disorder and Schizophrenia
Paris (ots/PRNewswire) - - For Healthcare and Medical Reporters (non-US) Bipolar disorder is the sixth largest cause of disability worldwide in people aged 15-44 years[1] and is commonly mistaken for other diseases such as acute depression. Consequently, people may suffer with symptoms for years before receiving appropriate treatment and up to half of all ...
mehr
14.09.2006 – 16:10
Boston Scientific
Safety and Efficacy of Drug-Eluting Stents Reaffirmed in New England Journal of Medicine Articles and Editorial
Natick, Massachusetts (ots/PRNewswire) - Boston Scientific Corporation (NYSE: BSX) today welcomed the results of two studies and an editorial published in today's edition of The New England Journal of Medicine (NEJM), all of which reaffirmed the safety and efficacy of drug-eluting stents. Commenting on the ...
mehr
14.09.2006 – 14:08
The Bill & Melinda Gates Foundation
Gates Foundation Commits Nearly US$70 Million to Help Fight Neglected Tropical Diseases
Seattle (ots/PRNewswire) - - Four Grants Support Development of Vaccines and Better Drugs, and Launch of New Medical Journal The Bill & Melinda Gates Foundation today announced four grants totaling US$68.2 million to help accelerate research on neglected tropical diseases, including hookworm, leishmaniasis, and trypanosomiasis, which kill or disable ...
mehr
14.09.2006 – 11:04
Eli Lilly and Company
Study Demonstrated Once-Weekly Exenatide LAR Improved Glucose Control in Patients with Type 2 Diabetes
Copenhagen, Denmark (ots/PRNewswire) - Eli Lilly and Company (NYSE: LLY), Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), and Alkermes, Inc. (Nasdaq: ALKS) today announced detailed results from a safety and efficacy study of the long-acting release (LAR) formulation of exenatide. Data from the study demonstrated ...
mehr
14.09.2006 – 09:08
Pfizer AG
Exubera Effective in Diabetes Patients who Have Respiratory Infections or are Exposed to Passive Cigarette Smoke, New Analyses Show
Copenhagen, Denmark (ots/PRNewswire) - - Twice as Many People With Uncontrolled Type 2 Diabetes Would Accept Insulin if Offered Exubera, Even in Countries Where Pens are Commonly Used, Additional Study Shows - Patients With Diabetes Gained Less Weight With Exubera Than With Injectable ...
mehr
14.09.2006 – 08:04
Shire Pharmaceuticals Group Plc
New Treatment a Success for Anaemia Associated With Chronic Kidney Disease
Basingstoke, England (ots/PRNewswire) - - Not for Distribution in the United States The first anti-anaemia treatment produced in a human cell line, DYNEPO(R) (epoetin delta), can effectively control anaemia in patients with chronic kidney disease (CKD[x]) according to two Phase III studies presented for the first time today.(1),(2) Patients with kidney ...
mehr

13.09.2006 – 08:27
Gemalto
Gemplus Trading Update
Luxembourg (ots/PRNewswire) - Gemplus International S.A. (Euronext LU0121706294 - GEM and NASDAQ:GEMP), a world leading player in the secure card industry and a subsidiary of Gemalto N.V. (Euronext NL0000400653 - GTO), announces today that it no longer expects to meet its financial performance outlook for 2006. The Company cited market conditions that will remain challenging and uncertainties in the global economic environment. Because of the level of its integration ...
mehr
12.09.2006 – 18:19
Pfizer AG
Exubera Hailed as Innovation In Prestigious European and American Awards
New York (ots/PRNewswire) - - WSJ/Professor Pedro Nueno: "The drug could encourage diabetes sufferers to get treatment earlier and more often. This has such a tremendous advantage for a huge number of people worldwide. It is a real breakthrough." - PharmaBarometer: "Despite only being launched into the German market in May 2006, it has been immediately ...
mehr
12.09.2006 – 16:56
Medify Solutions Ltd.
Medify Solutions Limited (Pink Sheets - MFYS) - Forward Order Book
Gateshead, England (ots/PRNewswire) - Medify Solutions Limited (Pink Sheets - MFYS), today received partner approval to release the current forward order book. These figures include all current and forward sales for both the UK and European operations. Medify Solutions Limited is contracted to deliver the MedifyRemote application to the UK and the Italian ...
mehr
11.09.2006 – 15:12
Medify Solutions Ltd.
Medify Solutions Limited: Investors Update September 2006
Toronto, Canada (ots/PRNewswire) - Medify Solutions Limited (Pink Sheets - MFYS) today issued the latest investors update. The update is available to view on the company's website, www.medifysolutions.com under the latest news section. Company website : www.medifysolutions.com This news release contains forward-looking statements that are subject to certain risks and uncertainties that may cause actual results ...
mehr
11.09.2006 – 10:02
AstraZeneca GmbH
New Website Looks at the Science Behind Stroke
Macclesfield, England (ots/PRNewswire) - - www.novelneuroprotection.com Aims to Increase Understanding of Acute Ischemic Stroke and the Potential Role of Neuroprotection - For Medical Media Only A new resource for the international medical community was launched in September 2006 by AstraZeneca, www.novelneuroprotection.com. This educational site aims to help healthcare professionals understand more about ...
mehr
08.09.2006 – 22:37
sanofi-aventis Group
The New England Journal of Medicine Publishes the STEEPLE Study Which Demonstrated Superior Safety Profile of LOVENOX(r) (Enoxaparin Sodium Injection) Vs. Unfractionated Heparin (UFH) in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention
Paris (ots/PRNewswire) - The New England Journal of Medicine publishes the international STEEPLE trial (Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI): An International Randomized Evaluation), which showed that a single intravenous bolus of enoxaparin of 0.5 mg/kg is associated ...
mehr

Vorherige75767778798081828384Nächste